Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants
Sign Up to like & getrecommendations! Published in 2021 at "Virologica Sinica"
DOI: 10.1007/s12250-021-00409-4
Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has precipitated multiple variants resistant to therapeutic antibodies. In this study, 12 high-affinity antibodies were generated from convalescent donors in early outbreaks using immune antibody phage display libraries.… read more here.
Keywords: cocktail exhibits; cov variants; antibody cocktail; neutralization ... See more keywords
Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.980435
Abstract: Monoclonal antibodies (mAbs) targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have demonstrated clinical efficacy in preventing or treating coronavirus disease 2019 (COVID-19), resulting in the emergency use authorization (EUA) for several… read more here.
Keywords: antibody cocktail; non competing; amubarvimab romlusevimab; sars cov ... See more keywords
REGEN-COV® antibody cocktail bioanalytical strategy: comparison of LC-MRM-MS and immunoassay methods for drug quantification
Sign Up to like & getrecommendations! Published in 2021 at "Bioanalysis"
DOI: 10.4155/bio-2021-0190
Abstract: Aim: In response to the COVID-19 pandemic, Regeneron developed the anti-SARS-CoV-2 monoclonal antibody cocktail, REGEN-COV® (RONAPREVE® outside the USA). Drug concentration data was important for determination of dose, so a two-part bioanalytical strategy was implemented… read more here.
Keywords: drug; regen cov; bioanalytical strategy; antibody cocktail ... See more keywords